RT Journal Article
SR Electronic
T1 Drug eluting stents versus bare metal stents for the treatment of extracranial vertebral artery disease: a meta-analysis
JF Journal of NeuroInterventional Surgery
JO J NeuroIntervent Surg
FD BMJ Publishing Group Ltd.
SP 770
OP 774
DO 10.1136/neurintsurg-2015-011697
VO 8
IS 8
A1 Tank, Vivek H
A1 Ghosh, Ritam
A1 Gupta, Vikas
A1 Sheth, Nakul
A1 Gordon, Shariyah
A1 He, Wenzhuan
A1 Modica, Steven F
A1 Prestigiacomo, Charles J
A1 Gandhi, Chirag D
YR 2016
UL http://jnis.bmj.com/content/8/8/770.abstract
AB Background While a growing number of reports offer evidence for the potential of drug eluting stents (DES) in treating atherosclerotic stenosis of the extracranial vertebral artery, their efficacy when compared with bare metal stents (BMS) is uncertain due to the lack of a large prospective randomized trial.Methods A search strategy using the terms ‘stents’, ‘drug-eluting stents’, ‘atherosclerosis’, ‘vertebral artery’, and ‘vertebrobasilar insufficiency’ was employed through Medline. Five studies met the criteria for a comparative meta-analysis. The technical/clinical success, periprocedural complications, target vessel revascularization (TVR), rates of restenosis, recurrent symptoms, and overall survival were compared.Results There was no significant difference in the technical success (OR=1.528, p=0.622), clinical success (OR=1.917, p=0.274), and periprocedural complications (OR=0.741, p=0.614) between the two groups. An OR of 0.388 for no restenosis in the BMS to DES arms (p=0.001) indicated a significantly higher restenosis rate in the BMS group relative to the DES group (33.57% vs 15.49%). When compared with the DES group, the BMS group had a significantly higher rate of recurrent symptoms (2.76% vs 11.26%; OR=3.319, p=0.011) and TVR (4.83% vs 19.21%; OR=4.099, p=0.001).Conclusions A significantly lower rate of restenosis, recurrent symptoms, and TVR was noted in the DES group compared with the BMS group.